Prevalence and characteristics of persistent symptoms after non-severe COVID-19: a prospective cohort study

Armange, Lucas; Bénézit, François; Picard, Léa; Pronier, Charlotte; Guillot, Samuel; Lentz, Pierre-Axel; Carré, François; Tattevin, Pierre; Revest, Matthieu

doi:10.1007/s10096-021-04261-y

Cited by 20 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The frequency of anxiety, anosmia, agueusia, ENT, cardiological, neurological, painful, psychiatric symptoms were similar to other studies [11][12][13]15,19,20].…”

Section: Discussionsupporting

confidence: 89%

“…Persistent anxiety after COVID-19 infection is frequently described in the literature [16,20]. In our study 17 patients (23%) had persistent anxiety 6 months after infection.…”

Section: Discussionsupporting

confidence: 52%

“…All patients seen in consultation had normal auscultation and oxygen saturation and chest CT scan showed no or minimal abnormality (<10%). Another study showed similar results [20]. McGroder et al showed that there was no correlation between persistent dyspnea and chest CT scan abnormalities at 4-month follow-up [39].…”

Section: Discussionmentioning

confidence: 58%

“…Some studies found a higher rate of persistent symptoms but only looked at hospitalized patients [17,18]. On the opposite, other studies found a lower rate but only included patients treated as outpatient [14,19,20]. Moreno-Pérez and al.…”

Section: Discussionmentioning

confidence: 99%

“…found that 50.9% of patients had at least one symptom at 3 months but they did not take into account psychological symptoms that may have underestimated their results [21]. Regarding the nature of persistent symptoms, the two most frequent were asthenia and dyspnea according to the literature [12,[15][16][17][18][19][20][21][22][23][24][25].…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

COVEVOL: Natural Evolution at 6 Months of COVID-19

Messin

Puyraveau

Benabdallah

et al. 2021

Viruses

View full text Add to dashboard Cite

Many studies have investigated post-COVID symptoms, but the predictors of symptom persistence remain unknown. The objective was to describe the natural course of the disease at 6 months and to identify possible factors favoring the resurgence or persistence of these symptoms. COVEVOL is a retrospective observational descriptive study of 74 patients. All patients with positive SARS-CoV-2 PCR from March 2020 were included. We compared a group with symptom persistence (PS group) with another group without symptom persistence (no-PS group). Fifty-three out of seventy-four patients (71.62%) described at least one persistent symptom at 6 months of SARS-CoV-2 infection. In the PS group, 56.6% were women and the average age was 54.7 years old [21-89.2] ±16.9. The main symptoms were asthenia (56.6%, n = 30), dyspnea (34%, n = 18), anxiety (32.1% n = 17), anosmia (24.5%, n = 13) and agueusia (15.1% n = 8). Ten patients (13.51%) presented a resurgence in symptoms. Patients in the PS group were older (p = 0.0048), had a higher BMI (p = 0.0071), and were more frequently hospitalized (p = 0.0359) compared to the no-PS group. Odynophagia and nasal obstruction were less present in the inaugural symptoms of COVID-19 in the PS group (p = 0.0202 and p = 0.0332). Persistent post-COVID syndromes are common and identification of contributing factors is necessary for understanding this phenomenon and appropriate management.

show abstract

“…The frequency of anxiety, anosmia, agueusia, ENT, cardiological, neurological, painful, psychiatric symptoms were similar to other studies [11][12][13]15,19,20].…”

Section: Discussionsupporting

confidence: 89%

“…Persistent anxiety after COVID-19 infection is frequently described in the literature [16,20]. In our study 17 patients (23%) had persistent anxiety 6 months after infection.…”

Section: Discussionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

COVEVOL: Natural Evolution at 6 Months of COVID-19

Messin

Puyraveau

Benabdallah

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

Persistent chest pain following COVID‐19 infection – A scoping review

Kubrova,

Hallo‐Carrasco,

Klasova

et al. 2024

PM&R

View full text Add to dashboard Cite

IntroductionPersistent chest pain (PCP) following acute COVID‐19 infection is a commonly reported symptom with an unclear etiology, making its management challenging. This scoping review aims to address the knowledge gap surrounding the characteristics of PCP following COVID‐19, its causes, and potential treatments.ObjectiveTo assess the prevalence, causes, and potential treatments of PCP following COVID‐19 infection.DesignA scoping review of 64 studies, including observational (prospective, retrospective, cross‐sectional, case series, and case‐control) and one quasi‐experimental study, from databases including Embase, PubMed/MEDLINE, Cochrane CENTRAL, Google Scholar, Cochrane Database of Systematic Reviews, and Scopus.SettingStudies on patients with PCP following mild, moderate, and severe COVID‐19 infection.PatientsStudies that included patients of any age, with chest pain that persisted following acute COVID‐19 disease, irrespective of etiology or duration.InterventionsNot applicable.Main Outcome Measure(s)Prevalence, causes, and potential treatments of PCP following COVID‐19 infection.ResultsA total of 35 studies reported PCP symptoms following COVID‐19 (0.24‐76.6%) at an average follow‐up of three months or longer, 12 studies at 1‐3 months and 17 studies at less than one month follow‐up or not specified. PCP was common following mild ‐ severe COVID‐19 infection, and etiology was mostly not reported. Fourteen studies proposed potential etiologies including endothelial dysfunction, cardiac ischemia, vasospasm, myocarditis, cardiac arrhythmia, pneumonia, pulmonary embolism, postural tachycardia syndrome (POTS), or noted cardiac MRI (cMRI) changes. Evaluation methods included common cardiopulmonary tests, as well as less common tests such as flow‐mediated dilatation (FMD), cMRI, single‐photon emission computed tomography myocardial perfusion imaging (SPECT‐MPI), and cardiopulmonary exercise testing (CPET). Only one study reported a specific treatment (sulodexide).ConclusionsPCP is a prevalent symptom following COVID‐19 infection, with various proposed etiologies. Further research is needed to establish a better understanding of the causes and to develop targeted treatments for PCP following COVID‐19.This article is protected by copyright. All rights reserved.

show abstract

Kognitive Störungen und Schlafstörungen bei Long-COVID

2022

View full text Add to dashboard Cite

Hintergrund In den letzten 2 Jahren der COVID-19(„coronavirus disease 2019“)-Pandemie ist das Wissen um Langzeitfolgen der Erkrankung, das sog. „Long-COVID“, rapide gewachsen. Es bleiben jedoch noch viele Fragen offen, v. a. was die Ursachen überdauernder Beschwerden und ihre Prognose betrifft. Kognitive Störungen und Schlafstörungen gehören zu den häufig beklagten Beschwerden. Beide gehen mit starkem Leidensdruck und deutlicher Alltagsbeeinträchtigung einher. Ziel der Arbeit Wie ist die Datenlage zum Auftreten kognitiver Störungen und Schlafstörungen bei Long-COVID? Welches sind Einflussfaktoren und was ist bekannt zum Verlauf und zu möglichen zugrunde liegenden Mechanismen? Welche Therapieoptionen gibt es? Material und Methode In einem narrativen Review werden die wichtigsten Befunde zu kognitiven Störungen und Schlafstörungen bei Long-COVID dargestellt. Es wird ein Überblick gegeben über die Kohortenstudien mit Daten zu Prävalenz und Einflussfaktoren beider Symptomkomplexe. Es werden derzeitige Kenntnisse und Hypothesen zu pathophysiologischen Mechanismen dargestellt und ein Ausblick auf Behandlungsansätze gegeben. Ergebnisse Etwa ein Fünftel der Betroffenen berichtet mehr als 3 Monate nach einer SARS-CoV-2(„severe acute respiratory syndrome coronavirus 2“)-Infektion über kognitive Einschränkungen, etwa ein Drittel über Schlafstörungen, wobei es neben insomnischen auch zu hypersomnische Beschwerden kommt. Kognitive Störungen und Schlafstörungen treten bei Betroffenen aller Schweregrade auf. Es gibt Hinweise auf eine Besserung kognitiver Defizite im Verlauf, allerdings sind weitere Längsschnittstudien notwendig. Diskussion Neben der Prognose sind die zugrunde liegenden Krankheitsmechanismen noch unzureichend verstanden. Zudem besteht großer Forschungsbedarf zur Wirksamkeit und zu spezifischen Wirkfaktoren therapeutischer Interventionen .

show abstract

Prevalence and characteristics of persistent symptoms after non-severe COVID-19: a prospective cohort study

Cited by 20 publications

References 10 publications

COVEVOL: Natural Evolution at 6 Months of COVID-19

COVEVOL: Natural Evolution at 6 Months of COVID-19

Persistent chest pain following COVID‐19 infection – A scoping review

Kognitive Störungen und Schlafstörungen bei Long-COVID

Contact Info

Product

Resources

About